Bio-Rad Laboratories, Inc. (NYSE:BIO) Holdings Boosted by Rowland & Co. Investment Counsel ADV

Rowland & Co. Investment Counsel ADV lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating) by 101.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,337 shares of the medical research company’s stock after acquiring an additional 674 shares during the period. Rowland & Co. Investment Counsel ADV’s holdings in Bio-Rad Laboratories were worth $1,010,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in BIO. FMR LLC boosted its position in shares of Bio-Rad Laboratories by 12.7% during the 1st quarter. FMR LLC now owns 182,762 shares of the medical research company’s stock valued at $55,867,000 after purchasing an additional 20,560 shares in the last quarter. Rafferty Asset Management LLC grew its stake in Bio-Rad Laboratories by 53.6% in the third quarter. Rafferty Asset Management LLC now owns 685 shares of the medical research company’s stock valued at $511,000 after purchasing an additional 239 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Bio-Rad Laboratories by 25.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 78,786 shares of the medical research company’s stock worth $58,770,000 after purchasing an additional 15,747 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Bio-Rad Laboratories by 12.8% during the 3rd quarter. American Century Companies Inc. now owns 839 shares of the medical research company’s stock worth $626,000 after purchasing an additional 95 shares in the last quarter. Finally, Public Sector Pension Investment Board lifted its holdings in shares of Bio-Rad Laboratories by 3.1% during the 3rd quarter. Public Sector Pension Investment Board now owns 3,630 shares of the medical research company’s stock valued at $2,708,000 after buying an additional 110 shares during the last quarter. Institutional investors own 63.66% of the company’s stock.

A number of equities analysts recently commented on BIO shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $700.00 price objective on shares of Bio-Rad Laboratories in a research report on Friday, April 29th. StockNews.com began coverage on shares of Bio-Rad Laboratories in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Citigroup decreased their price target on shares of Bio-Rad Laboratories from $800.00 to $750.00 in a report on Monday, May 2nd. Zacks Investment Research upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $526.00 price objective on the stock in a research note on Wednesday, May 4th. Finally, TheStreet downgraded Bio-Rad Laboratories from a “b-” rating to a “c+” rating in a research note on Thursday, April 28th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $726.50.

NYSE BIO traded down $10.16 during midday trading on Wednesday, hitting $508.57. The company had a trading volume of 173,928 shares, compared to its average volume of 231,205. The firm has a fifty day simple moving average of $541.17 and a two-hundred day simple moving average of $624.33. Bio-Rad Laboratories, Inc. has a fifty-two week low of $468.86 and a fifty-two week high of $832.70. The company has a quick ratio of 4.16, a current ratio of 5.10 and a debt-to-equity ratio of 0.12. The stock has a market cap of $15.23 billion, a price-to-earnings ratio of -106.30 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIOGet Rating) last released its earnings results on Thursday, April 28th. The medical research company reported $4.94 earnings per share for the quarter, topping analysts’ consensus estimates of $2.80 by $2.14. The business had revenue of $700.10 million for the quarter, compared to the consensus estimate of $678.00 million. Bio-Rad Laboratories had a positive return on equity of 3.66% and a negative net margin of 3.49%. The firm’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period last year, the business earned $5.21 earnings per share. As a group, equities analysts predict that Bio-Rad Laboratories, Inc. will post 14.2 earnings per share for the current year.

Bio-Rad Laboratories Company Profile (Get Rating)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Featured Articles

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.